CN113347993A - 突变牛痘病毒及其用途 - Google Patents

突变牛痘病毒及其用途 Download PDF

Info

Publication number
CN113347993A
CN113347993A CN201980084497.0A CN201980084497A CN113347993A CN 113347993 A CN113347993 A CN 113347993A CN 201980084497 A CN201980084497 A CN 201980084497A CN 113347993 A CN113347993 A CN 113347993A
Authority
CN
China
Prior art keywords
ala
vaccinia virus
ile
amino acid
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980084497.0A
Other languages
English (en)
Chinese (zh)
Inventor
宋晓彤
M·维斯科夫斯卡
M·L·戈麦斯梅达利亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isao Clarks Therapy Co ltd
Original Assignee
Isao Clarks Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isao Clarks Therapy Co ltd filed Critical Isao Clarks Therapy Co ltd
Publication of CN113347993A publication Critical patent/CN113347993A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980084497.0A 2018-10-22 2019-10-21 突变牛痘病毒及其用途 Pending CN113347993A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862749102P 2018-10-22 2018-10-22
US62/749,102 2018-10-22
US201962912344P 2019-10-08 2019-10-08
US62/912,344 2019-10-08
PCT/US2019/057134 WO2020086423A1 (en) 2018-10-22 2019-10-21 Mutant vaccinia viruses and use thereof

Publications (1)

Publication Number Publication Date
CN113347993A true CN113347993A (zh) 2021-09-03

Family

ID=70331869

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980084497.0A Pending CN113347993A (zh) 2018-10-22 2019-10-21 突变牛痘病毒及其用途

Country Status (10)

Country Link
US (1) US20210388388A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870217A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022508942A (cg-RX-API-DMAC7.html)
KR (1) KR20210108944A (cg-RX-API-DMAC7.html)
CN (1) CN113347993A (cg-RX-API-DMAC7.html)
AU (1) AU2019367965A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117378A1 (cg-RX-API-DMAC7.html)
IL (1) IL282509A (cg-RX-API-DMAC7.html)
MX (1) MX2021004403A (cg-RX-API-DMAC7.html)
WO (1) WO2020086423A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114369587A (zh) * 2021-12-25 2022-04-19 苏州瀚源新酶生物科技有限公司 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用
CN116179654A (zh) * 2022-12-30 2023-05-30 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用
CN116990507A (zh) * 2023-06-29 2023-11-03 深圳市新产业生物医学工程股份有限公司 一种用于猴痘病毒感染的早期筛查的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
EP4299729A4 (en) * 2021-02-26 2025-06-11 SillaJen, Inc. ONCOLYTIC VIRUS AND USE THEREOF
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN113322279A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种敲除d8l基因的重组痘苗病毒载体
CN113481240A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除l1r基因的重组痘苗病毒载体
CN113481241A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除h3l基因的重组痘苗病毒载体
CN113322280A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058643A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058645A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058644A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
KR102983542B1 (ko) * 2022-06-29 2026-06-30 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165477A1 (en) * 2000-04-14 2003-09-04 Jean-Marc Balloul Poxvirus with targeted infection specificity
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
WO2009026456A2 (en) * 2007-08-21 2009-02-26 University Of Massachusetts Poxvirus methods and compositions
CN102573902A (zh) * 2009-11-05 2012-07-11 分子医学和免疫学中心 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
JP4344805B2 (ja) * 2000-07-07 2009-10-14 独立行政法人科学技術振興機構 遺伝子組換えワクシニアウイルスワクチン
JP4802401B2 (ja) * 2000-11-07 2011-10-26 トランスジェン・ソシエテ・アノニム 標的化感染特異性を有するポックスウイルス
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
FI20115914L (fi) * 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
MY200887A (en) * 2016-08-19 2024-01-22 Sementis Ltd Viral Vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165477A1 (en) * 2000-04-14 2003-09-04 Jean-Marc Balloul Poxvirus with targeted infection specificity
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
WO2009026456A2 (en) * 2007-08-21 2009-02-26 University Of Massachusetts Poxvirus methods and compositions
CN102573902A (zh) * 2009-11-05 2012-07-11 分子医学和免疫学中心 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114369587A (zh) * 2021-12-25 2022-04-19 苏州瀚源新酶生物科技有限公司 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用
CN114369587B (zh) * 2021-12-25 2024-03-15 苏州瀚源新酶生物科技有限公司 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用
CN116179654A (zh) * 2022-12-30 2023-05-30 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用
CN116179654B (zh) * 2022-12-30 2023-09-15 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用
CN116990507A (zh) * 2023-06-29 2023-11-03 深圳市新产业生物医学工程股份有限公司 一种用于猴痘病毒感染的早期筛查的方法

Also Published As

Publication number Publication date
MX2021004403A (es) 2021-10-22
JP2022508942A (ja) 2022-01-19
US20210388388A1 (en) 2021-12-16
AU2019367965A1 (en) 2021-06-03
EP3870217A1 (en) 2021-09-01
KR20210108944A (ko) 2021-09-03
WO2020086423A1 (en) 2020-04-30
CA3117378A1 (en) 2020-04-30
IL282509A (en) 2021-06-30
EP3870217A4 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
KR20210108944A (ko) 돌연변이 백시니아 바이러스 및 이의 용도
KR102857666B1 (ko) 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
KR102854512B1 (ko) B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
US7429481B2 (en) Targeting viruses using a modified sindbis glycoprotein
US12358994B2 (en) Antibody-modified chimeric antigen receptor modified T cell and uses thereof
CN109862912A (zh) 携带双特异性T细胞衔接器(BiTE)的腺病毒
CN108018299A (zh) 靶向bcma的嵌合抗原受体及其用途
JP7190166B2 (ja) 改変糖タンパク質dを有するヘルペスウイルス
JP2024054286A (ja) 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
EP3624836A1 (en) Cell
CN108004259A (zh) 靶向b细胞成熟抗原的嵌合抗原受体及其用途
WO2021071534A1 (en) Mutant vaccinia viruses and use thereof
CN112661857B (zh) 一种嵌合抗原受体及其用途
KR20210111237A (ko) 암세포 표적화 영역과 hvem의 세포외 도메인의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
KR20190020727A (ko) 변형된 당단백질 b를 갖는 헤르페스 바이러스
CN112368007A (zh) 抗原隐匿的溶瘤病毒
KR20220151611A (ko) 암 세포, 면역 세포 및 종양 미세환경으로의 시알리다제의 전달
CN116133671A (zh) 重组牛痘病毒
KR20240005849A (ko) 종양용해성 hsv의 범용 재표적화
WO2019128996A1 (zh) 自表达cd47抗体的间皮素特异性car-t细胞及其用途
WO2020029274A1 (zh) 一种减毒棒状病毒的制备方法及应用
HK40088967A (en) Recombinant vaccinia virus
HK40109559A (en) Universal retargeting of oncolytic hsv
WO2026107113A1 (en) MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF
KR20230105035A (ko) 재조합 백시니아 바이러스

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210903